ATG and RIC: Not such a good match?

Blood

Volumn 117, Issue 25, 2011, Pages 6744-6745

  Giralt, Sergio ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; THYMOCYTE ANTIBODY;

ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOTHERAPY; NOTE; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING;

EID: 79959492267     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-348433     Document Type: Note

References (7)

1. Mathe G, Kiger N, Florintin I, et al. Progress in the prevention of GVH: bone marrow grafts after ALG conditioning, with lymphocyte split chimerism, use of a lymphocyte "chalone T", and soluble histocompatibility antigens. Transplant Proc. 1973;5(1):933-939.
2. Weiden PL, Doney K, Storb R, Thomas ED. Anti-human thymocyte globulin (ATG) for prophylaxis and treatment of graft-versus-host disease in recipients of allogeneic marrow grafts. Transplant Proc. 1978;10(1):213-216.
3. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942-2947.
4. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomized, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855-864.
5. Soiffer RJ, LeRademacher J, Ho V, Kan F, Artz A, Champlin RE, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117(25):6963-6970.
6. Chakraverty R, Orti G, Roughton M, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD and immune reconstitution. Blood. 2010;116(16):3080-3088.
7. Giralt S, Logan B, Rizzo D, Zhang M, Ballen K, Emmanouilides C, et al. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Transplantation. 2007;13(7):844-852. (Pubitemid 46902440)